Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Nasdaq 100 Movers: GILD, EA

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 10:36am EDT

In early trading on Tuesday, shares of Electronic Arts (EA) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.8%. Year to date, Electronic Arts registers a 27.9% gain.

And the worst performing Nasdaq 100 component thus far on the day is Gilead Sciences (GILD), trading down 4.6%. Gilead Sciences is showing a gain of 3.2% looking at the year to date performance.

Two other components making moves today are Take-Two Interactive Software (TTWO), trading down 4.3%, and JD. om (JD), trading up 3.6% on the day.

© BNK Invest, source Videos

Stocks mentioned in the article
ChangeLast1st jan.
ELECTRONIC ARTS 0.77% 93.525 Delayed Quote.19.31%
GILEAD SCIENCES 1.43% 64.99 Delayed Quote.2.54%
TAKE-TWO INTERACTIVE SOFTWARE 1.08% 93.84 Delayed Quote.-9.04%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08:25aGILEAD SCIENCES : Announces Topline Data from Phase 3 STELLAR-3 Study of Selonse..
AQ
04/25GILEAD SCIENCES : Phase 3 Selonsertib Study Misses Primary Endpoint
DJ
04/25GILEAD SCIENCES : Announces Topline Data From Phase 3 STELLAR-3 Study of Selonse..
BU
04/24GILEAD SCIENCES : Kite Announces Plans for New State-of-the-Art Facility to Expa..
BU
04/23GILEAD SCIENCES : Development Veteran Steven J. Knox Joins Assembly Biosciences ..
AQ
04/19GILEAD SCIENCES : And insitro Announce Strategic Collaboration To Discover And D..
AQ
04/18GILEAD SCIENCES : to Release First Quarter 2019 Financial Results on Thursday, M..
BU
04/18NOVO NORDISK : Gilead doubles down on NASH with two deals in one week
AQ
04/16GILEAD SCIENCES : and Novo partner to trial combination therapy for NASH
AQ
04/16GILEAD SCIENCES : announces Novo Nordisk NASH partnership after new data reveale..
AQ
More news
Financials ($)
Sales 2019 21 975 M
EBIT 2019 11 271 M
Net income 2019 6 738 M
Debt 2019 8 872 M
Yield 2019 3,95%
P/E ratio 2019 12,04
P/E ratio 2020 11,09
EV / Sales 2019 4,12x
EV / Sales 2020 3,49x
Capitalization 81 772 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 81,2 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES2.54%81 772
VERTEX PHARMACEUTICALS4.15%44 640
REGENERON PHARMACEUTICALS-6.29%37 577
GENMAB3.51%10 164
SAREPTA THERAPEUTICS INC10.16%8 857
BLUEBIRD BIO INC40.02%7 656